Answers are grounded in this paper and cite their sources.
Overall, a lack of well powered human in vivo studies assessing the pharmacogenetics in pain patients treated with NSAIDs or antidepressants is noted. Studies indicate a higher risk for partly severe side effects for the CYP2C9 poor metabolizers and NSAIDs. Further in vivo studies are needed to consolidate the relevant polymorphisms in NSAID safety as well as in the efficacy of NSAIDs and antidepressants in pain management.
No takes yet. Share an insight, caveat, or question.
Zobdeh et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: